A global leader in pharmaceuticals has finalized a dual-site agreement with AGC Biologics, committing over €0.5 billion to bolster the production of commercial biologics. This strategic move merges manufacturing capabilities in Copenhagen and Yokohama, underscoring a growing focus on flexible, resilient supply chains in the healthcare industry.